ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

telpegfilgrastim

Its studies are mostly in Pre-Eclampsia, led by Xiamen Amoytop Biotech.

Drug pageTelpegfilgrastim: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 1, since Mar 6, 20252 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Xiamen Amoytop Biotech20 open or runningphase 1since Mar 6, 2025Mar 6, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2020Named telpegfilgrastimINNProposed as its International Nonproprietary Name in WHO's List 123
  2. Mar 6, 2025First study: phase 1 study in Pre-EclampsiaFirst studyNCT06893796 · 18 enrolled · China
  3. Apr 3, 2025Phase 1 study in Pre-EclampsiaNCT06924385 · 18 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06924385Pre-Eclampsia · China1CompletedJan 20, 202618
NCT06893796Pre-Eclampsia · China1CompletedMay 8, 202518

How it is read

Names in the registry

  • “Telpegfilgrastim Injection”, 8 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.